`
`Washington, D.C.
`
`In the Matter of
`
`CERTAIN PRE-FILLED SYRINGES FOR
`INTRA VITREAL INJECTION AND
`COMPONENTS THEREOF
`
`INV. NO. 337-TA-1207
`
`ORDER NO. 20: MODIFYING THE PROCEDURAL SCHEDULE
`
`(December 10, 2020)
`
`On December 9, 2020, complainants Nova1tis Phatma AG, Novattis Phatmaceuticals
`
`Corporation, and Novattis Technology LLC ( collectively, "Novattis") and respondent Regeneron
`
`Phatmaceuticals, Inc. ("Regeneron") filed a joint motion ("Mot.") seeking to modify ce1tain dates in
`
`the procedural schedule issued as Order No. 8 on August 17, 2020. Motion Docket No. 1207-017.
`
`The Commission Investigative Staff does not oppose the requested relief. See Mot. at 1.
`
`Unopposed Motion No. 1207-017 is granted. The remainder of this investigation shall be
`
`conducted in accordance with the following schedule:
`
`Event
`
`Fact discove1y cutoff and completion
`
`Deadline for final contentions on issues for which the
`patty bears the burden of proof
`
`Deadline for final contentions on issues for which the
`patty does not bear the burden of proof
`
`Date
`
`December 18, 2020
`
`December 23, 20201
`
`December 23, 2020
`
`Deadline for motions to compel discove1y
`
`December 29, 2020
`
`1 Dates that differ from those set fo1th in Order No. 8 are indicated by italic typeface.
`
`Novartis Exhibit 2048.001
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`Event
`
`Monthly case management conference
`
`Exchange initial expe1i reports (identify
`tests/ surveys/ data)
`
`Exchange rebuttal expert repo1is
`
`One-day mediation session
`
`Monthly case management conference
`
`Date
`
`January 14, 2021
`at 10:30 a.m.
`
`January 22, 2021
`
`February 5, 2021
`
`By Febma1y 10, 2021
`
`February 18, 2021
`at 10:30 a.m.
`
`Deadline for filing sunnnaiy dete1mination motions
`
`Febma1y 18, 2021
`
`Expert discove1y cutoff and completion
`
`Exchange of exhibit lists among the paiiies of proposed
`direct exhibits
`
`Complainant and respondent se1ve proposed direct
`exhibits, and identify physical exhibits2
`
`Submit joint repo1i on mediation
`
`Staff se1ves proposed direct exhibits, and identifies
`physical exhibits
`
`Se1ve proposed rebuttal exhibits, and identify rebuttal
`physical exhibits
`
`Complainants and respondent file pre-trial statements and
`briefs
`
`Monthly case management conference
`
`File joint list of unopposed exhibits
`
`Staff files pre-trial statement and brief
`
`Deadline for motions in limine
`
`February 22, 2021
`
`February 24, 2021
`
`March 2, 2021
`
`March 3, 2021
`
`Mai·ch 5, 2021
`
`Mai·ch 9, 2021
`
`Mai·ch 12, 2021
`
`March 18, 2021
`at 10:30 a.m.
`
`March 23, 2021
`
`March 26, 2021
`
`Mai·ch 31 , 2021
`
`2 The paiiies represent they will separately stipulate as to a schedule for exchanging direct and
`rebuttal demonstratives and objections in the event of live testimony at the evidentiaiy hearing.
`
`2
`
`Novartis Exhibit 2048.002
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`Event
`
`Deadline for responses to motions in limine
`
`Date
`
`April 8, 2021
`
`Final pre-hearing conference
`
`April 16, 2021 at 9:00 a.m.
`
`Hearing
`
`File final exhibit list
`
`Complainant and respondent file post-hearing initial briefs
`with th e Secretaiy an d submit final exhibits with the
`Administrative Law Judge
`
`Staff files post-hearing initial brief
`
`Complainant and respondent file post-hearing responsive
`briefs
`
`Staff files post-hearing responsive brief
`
`Final initial determination
`
`April 19-23, 2021 at 9:00 a.m.
`
`April 29, 2021
`
`May 14, 2021
`
`May 21 , 2021
`
`May 28, 2021
`
`June 4, 2021
`
`July 29, 2021
`
`Target date for completion of investigation
`
`November 29, 2021
`
`SO ORDERED.
`
`Clark S. Cheney
`Administrative Law Judge
`
`3
`
`Novartis Exhibit 2048.003
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`CERTAIN PRE-FILLED SYRINGES
`FOR INTRAVITREAL INJECTION
`AND COMPONENTS THEREOF
`
`
`Inv. No. 337-TA-1207
`
`PUBLIC CERTIFICATE OF SERVICE
`
`I, Lisa R. Barton, hereby certify that the attached ORDER has been served via EDIS
`upon the Commission Investigative Attorney, W. Peter Guarnieri, Esq., and the following
`parties as indicated, on December 11, 2020.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`On Behalf of Complainants Novartis Pharma AG, Novartis
`Pharmaceuticals Corporation, and Novartis Technology LLC:
`
`Elizabeth J. Holland, Esq.
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Email: EHolland@goodwinlaw.com
`
`On Behalf of Respondent Regeneron Pharmaceuticals, Inc.:
`
`Anish R. Desai, Esq.
`WEIL, GOTSHAL & MANGES LLP
`767 5th Avenue
`New York, NY 10153
`Email: anish.desai@weil.com
`
`
`
`
`
`
`
`Lisa R. Barton, Secretary
`U.S. International Trade Commission
`500 E Street, SW, Room 112
`Washington, DC 20436
`
`
`
`
`☐ Via Hand Delivery
`☐ Via Express Delivery
`☐ Via First Class Mail
`☒ Other: Email Notification
`of Availability for Download
`
`
`
`☐ Via Hand Delivery
`☐ Via Express Delivery
`☐ Via First Class Mail
`☒ Other: Email Notification
`of Availability for Download
`
`Novartis Exhibit 2048.004
`Regeneron v. Novartis, IPR2020-01317
`
`